Materias dentro de su búsqueda.
Mostrando 486,441 - 486,460 Resultados de 487,202 Para Buscar '"free will"', tiempo de consulta: 2.14s Limitar resultados
  1. 486441
    “…Metabolism was moderate, with ~ 30% parent compound remaining for (R)-[(18)F]OF-Me-NB1 and 20% for (S)-[(18)F]OF-Me-NB1 at 30 min postinjection. Plasma free fraction was 1–2%. In brain regions, both (R)- and (S)-[(18)F]OF-Me-NB1 displayed fast uptake with slower clearance for the (R)- than (S)-enantiomer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Characterization in nonhuman primates of (R)-[(18)F]OF-Me-NB1 and (S)-[(18)F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor
  2. 486442
    “…Study endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: Of 450 MBM patients, 175 (38.9%) received CTLA-4+PD-1 ICB, 161 (35.8%) PD-1 ICB, and 114 (25.3%) BRAF+MEK TT as first-line treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
  3. 486443
    “…METHODS: In healthy premenopausal women with and without a BRCA mutation we studied (i) estrogen and progesterone levels in saliva over an entire menstrual cycle (n = 20); (ii) cancer-free normal breast-tissue from a control population who had no family or personal history of breast cancer and equivalently from BRCA1/2 mutation carriers (n = 28); triple negative breast cancer (TNBC) biopsies and healthy breast tissue taken from sites surrounding the TNBC in the same individuals (n = 14); and biopsies of ER+ve/PR+ve stage T1–T2 cancers and healthy breast tissue taken from sites surrounding the cancer in the same individuals (n = 31); and (iii) DNA methylation and DNA mutations in normal breast tissue (before and after treatment) from clinical trials that assessed the potential preventative effects of vitamins and antiprogestins (mifepristone and ulipristal acetate; n = 44). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women
  4. 486444
    “…RESULTS: A hematoendothelial population was obtained after 84 h of hPSC-EBs formation under serum-free conditions and isolated based on CD144 expression. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Endothelial and hematopoietic hPSCs differentiation via a hematoendothelial progenitor
  5. 486445
    “…The regimen composed of TDF, 3TC and EFV was still currently the preferred solution used free first-line therapy.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China
  6. 486446
    “…In addition to intermittent hypoxic exposure, rats were free to move in an additional compartment normoxia environment for 6 days per week for 3 weeks. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    EFFECTS OF INTERMITTENT HYPOXIA EXPOSURE ON LEUKOCYTE COUNT AND ANXIETY IN EXERCISE-INDUCED HYPOHEMOGLOBIN RATS
  7. 486447
    “…Secondary endpoints included safety profile, an immune response, including dynamic changes in immune cell and cytokine production, and progression-free survival (PFS). In a 3 + 3 dose-escalation design, the dosage levels for CpG ODN (K3) were 5 or 10 mg/body via subcutaneous injection and 0.2 mg/kg via intravenous administration on days 1, 8, 15, and 29. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study
  8. 486448
    “…We analyzed 1023 eligible cases who were classified into three subsets: IKZF1not-del: IKZF1-not-deleted (n = 835), IKZF1del: IKZF1deleted (n = 94) and IKZF1plus: IKZF1del plus deletion of other genes (n = 94). Leukemia-free-survival probability (standard deviation) (LFSp(SE)) was 75 (2)% for IKZF1not-del, 51 (6)% for IKZF1del and 48 (6)% for IKZF1plus (p-value < 0.00001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of IKZF1 Deletions in the Prognosis of Childhood Acute Lymphoblastic Leukemia in Argentina
  9. 486449
    “…METHODS: A partitioned survival model with a 28-day cycle and three health states (event-free survival (EFS), progressive/relapsed disease, and death) was developed to estimate costs and effectiveness of venetoclax + azacitidine versus azacitidine over a lifetime (25-year) horizon. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
  10. 486450
    “…Using iterative numerical algorithms, time-to-event individual patient data (IPD) were reconstructed and pooled to retrieve distribution-free summary survival curves, with recovery rates reported at 30 day intervals for participants who remained alive. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves
  11. 486451
    “…Primary endpoint was progression-free survival (PFS), with a one-sided p-value of 0.2 to demonstrate statistical significance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
  12. 486452
    por Felín, Mariangela Soberón, Wang, Kanix, Moreira, Aliya, Grose, Andrew, Leahy, Karen, Zhou, Ying, Clouser, Fatima Alibana, Siddiqui, Maryam, Leong, Nicole, Goodall, Perpetua, Michalowski, Morgan, Ismail, Mahmoud, Christmas, Monica, Schrantz, Stephen, Caballero, Zuleima, Norero, Ximena, Estripeaut, Dora, Ellis, David, Raggi, Catalina, Castro, Catherine, Moossazadeh, Davina, Ramirez, Margarita, Pandey, Abhinav, Ashi, Kevin, Dovgin, Samantha, Dixon, Ashtyn, Li, Xuan, Begeman, Ian, Heichman, Sharon, Lykins, Joseph, Villalobos-Cerrud, Delba, Fabrega, Lorena, Montalvo, José Luis Sanchez, Mendivil, Connie, Quijada, Mario R., Fernández-Pirla, Silvia, de La Guardia, Valli, Wong, Digna, de Guevara, Mayrene Ladrón, Flores, Carlos, Borace, Jovanna, García, Anabel, Caballero, Natividad, Rengifo-Herrera, Claudia, de Saez, Maria Theresa Moreno, Politis, Michael, Wroblewski, Kristen, Karrison, Theodore, Ross, Stephanie, Dogra, Mimansa, Dhamsania, Vishan, Graves, Nicholas, Kirchberg, Marci, Mathur, Kopal, Aue, Ashley, Restrepo, Carlos M., Llanes, Alejandro, Guzman, German, Rebellon, Arturo, Boyer, Kenneth, Heydemann, Peter, Noble, A. Gwendolyn, Swisher, Charles, Rabiah, Peter, Withers, Shawn, Hull, Teri, Su, Chunlei, Blair, Michael, Latkany, Paul, Mui, Ernest, Vasconcelos-Santos, Daniel Vitor, Villareal, Alcibiades, Perez, Ambar, Galvis, Carlos Andrés Naranjo, Montes, Mónica Vargas, Perez, Nestor Ivan Cardona, Ramirez, Morgan, Chittenden, Cy, Wang, Edward, Garcia-López, Laura Lorena, Muñoz-Ortiz, Juliana, Rivera-Valdivia, Nicolás, Bohorquez-Granados, María Cristina, de-la-Torre, Gabriela Castaño, Padrieu, Guillermo, Hernandez, Juan David Valencia, Celis-Giraldo, Daniel, Dávila, Juan Alejandro Acosta, Torres, Elizabeth, Oquendo, Manuela Mejia, Arteaga-Rivera, José Y., Nicolae, Dan L., Rzhetsky, Andrey, Roizen, Nancy, Stillwaggon, Eileen, Sawers, Larry, Peyron, Francois, Wallon, Martine, Chapey, Emanuelle, Levigne, Pauline, Charter, Carmen, De Frias, Migdalia, Montoya, Jose, Press, Cindy, Ramirez, Raymund, Contopoulos-Ioannidis, Despina, Maldonado, Yvonne, Liesenfeld, Oliver, Gomez, Carlos, Wheeler, Kelsey, Holfels, Ellen, Frim, David, McLone, David, Penn, Richard, Cohen, William, Zehar, Samantha, McAuley, James, Limonne, Denis, Houze, Sandrine, Abraham, Sylvie, Piarroux, Raphael, Tesic, Vera, Beavis, Kathleen, Abeleda, Ana, Sautter, Mari, El Mansouri, Bouchra, El Bachir, Adlaoui, Amarir, Fatima, El Bissati, Kamal, de-la-Torre, Alejandra, Britton, Gabrielle, Motta, Jorge, Ortega-Barria, Eduardo, Romero, Isabel Luz, Meier, Paul, Grigg, Michael, Gómez-Marín, Jorge, Kosagisharaf, Jagannatha Rao, Llorens, Xavier Sáez, Reyes, Osvaldo, McLeod, Rima
    Publicado 2022
    “…These were tested for efficacy as learning tools for high-school students, pregnant women, medical students, physicians, scientists, public health officials and general public. Digitized, free, smart phone application effectively taught pregnant women about toxoplasmosis prevention. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview
  13. 486453
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Burden of malaria in pregnancy among adolescent girls compared to adult women in 5 sub-Saharan African countries: A secondary individual participant data meta-analysis of 2 clinical trials
  14. 486454
    “…Compared with the low basophil group (≤ 20.0/μL, n = 40), the high basophil group (> 20.0/μL, n = 23) had a significantly lower objective response rate (ORR 17.4% vs. 67.5%, p = 0.0001), worse progression-free survival (median PFS 4.0 vs. 15.0 months, p = 0.0003), and worse overall survival (median OS not reached, p = 0.027). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer
  15. 486455
    “…BACKGROUND: Acute-on-chronic liver failure (ACLF) represents a rising global healthcare burden, characterised by increasing prevalence among patients with decompensated cirrhosis who have a 28-day transplantation-free mortality of 33.9%. Due to disease complexity and a high prevalence of socio-economic disadvantage, there are deficits in quality of care and adherence to guideline-based treatment in this cohort. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trial
  16. 486456
    por Pu, Qian, Zhao, Qianqian, Gao, Dezong
    Publicado 2022
    “…OBJECTIVE: To provide a rare case of local recurrent Paget’s disease after nipple-sparing mastectomy (NSM) with immediate breast reconstruction with 10 years of disease-free survival and to analyze the clinical and pathological characteristics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Local recurrence of mammary Paget’s disease after nipple-sparing mastectomy and implant breast reconstruction: a case report and literature review
  17. 486457
    por Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Å., Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., van Dam, R. M.
    Publicado 2022
    “…Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
  18. 486458
    “…Data were collected to compare the operative data, postoperative complications, duration of hospital stay, stone-free rate, and auxiliary procedure rate associated with RIRS and Mini pcnl for the treatment of 1–2 cm renal calculi. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prospective study on Comparison of outcomes of mini percutaneous nephrolithotomy versus retrograde intrarenal surgery for renal stones of 1–2 cm size
  19. 486459
    “…After a robust doubly adjustment on tumor number and size, vascular invasion, ALBI, MELD, and cirrhosis, the type of treatment did not impact OS (HR = 0.92, 95% CI: 0.27–3.15, p = 0.88) or progression-free survival (HR = 1.24, 95% CI: 0.44–3.49, p = 0.67). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma
  20. 486460
    “…Furthermore, progression-free survival (PFS) was significantly influenced by SNPs rs3732357 (HR = 0.2, 95% CI = 0.26-0.70; p = 0.001), rs3732360 (HR = 0.59; 95% CI = 0.38-0.93; p = 0.020), rs11917714 (HR = 0.58; 95% CI = 0.36-0.92; p = 0.020), and rs3732359 (HR = 0.57; 95% CI = 0.36-0.91; p = 0.024) in PXR; rs2307418 (HR = 2.02; 95% CI = 1.19-3.43; p = 0.048) in CAR; and rs2235023 (HR = 2.49; 95% CI = 1.13-5.50; p = 0.011) and rs22114102 (HR = 1.90; 95% CI = 1.00-3.63; p = 0.028) in ABCB1. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia
Herramientas de búsqueda: RSS